Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma model

2 Sept 2025

Abstract excerpt

Personalized neoantigen peptide vaccines have shown remarkable anti-tumor activity across diverse cancer types. With the rapid advancement of messenger RNA (mRNA) delivery technologies during the coronavirus disease of 2019 (COVID-19) pandemic, mRNA-based cancer vaccines have emerged as a promising therapeutic approach because of their scalable production, safety, and capacity to elicit potent immune responses....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40898321
DOI: 10.1186/s12951-025-03681-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma modelPMID 40898321Read ↗

Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinomaSemantic proximity Read ↗

Polymer-lipid hybrid nanoparticle enhances mRNA delivery and T cell-mediated immunitySemantic proximity Read ↗

LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatmentSemantic proximity Read ↗

High-throughput <i>in vivo</i> screening using barcoded mRNA identifies lipid nanoparticles with extrahepatic tropism for cancer immunotherapySemantic proximity Read ↗

Second generation of LNP based mRNA vaccine leads to a T cell–inflamed tumor microenvironment favorable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumor modelSemantic proximity Read ↗

Cd73-LNPs promotes antitumor T-cell immunity via amplifying Tlr3-mediated immunostimulatory dendritic cell activationSemantic proximity Read ↗

Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy.Semantic proximity Read ↗

mRNA Vaccine Platforms and Lipid Nanoparticle Delivery Systems: Molecular Advances, Clinical Breakthroughs, and Regulatory Perspectives (2020–2025)Semantic proximity Read ↗

Systemic trafficking of mRNA lipid nanoparticle vaccine following intramuscular injection generates potent tissue-specific T cell responseSemantic proximity Read ↗

Lipid Nanoparticles for Spleen-Targeted RNA deliverySemantic proximity Read ↗

Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactionsSemantic proximity Read ↗

Coordinated Tuning of Ionizable Lipids and Formulation Redirects mRNA Vaccines Toward Lymphoid-Specific CD4 <sup>+</sup> T Cell ImmunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.